Updated from ASH and ACCP – DOAC Dosing for VTE: What You Need to Know
Dr. Chokri Ben Lamine shared on X:
Based on ASH 2024 and ACCP 2021 Guidelines
”VTE Treatment (Therapeutic Anticoagulation)”
-Apixaban:
▸ 10 mg BID × 7 days → 5 mg BID
▸ Optional: 2.5 mg BID after 6 months (extended use)Rivaroxaban:
▸ 15 mg BID × 21 days → 20 mg OD
▸ Optional: 10 mg OD after 6 monthsEdoxaban:
▸ Parenteral anticoagulation × 5–10 days → 60 mg OD
▸ Reduce to 30 mg if CrCl 15–50 or weight ≤60 kgDabigatran:
▸ Parenteral anticoagulation × 5–10 days → 150 mg BIDVTE Prophylaxis (Post-op, High Risk)
-Apixaban: 2.5 mg BID-Rivaroxaban: 10 mg OD
-Dabigatran: 110 mg Day 1 → 220 mg OD
-Edoxaban: Not typically used for primary prophylaxis
Key Precautions
-Age >75-CrCl <30 mL/min
-Low body weight
-Active cancer → Consider LMWH
Always assess bleeding & renal function risk.”
You can Find more Posts on Hemostasis Today.
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies
-
May 26, 2026, 15:22Shazmah Shaikh: One Visual Guide to Understand All Major Anticoagulants
-
May 26, 2026, 14:39Chidinma Favour։ Welcome to Day 25 of My 31-Day Stroke Awareness Series
-
May 26, 2026, 14:35Novel Insights Into Congenital and Acquired Coagulopathies – ICHCC
-
May 26, 2026, 14:24Fernanda Orsi: The Growing Impact of Hematology Research in Latin America
-
May 26, 2026, 14:23Rense Buijvoets: What If Clots Could Be Treated Exactly Where They Form?
